Long Noncoding RNAs in Lung Cancer: From Disease Markers to Treatment Roles.
Long Noncoding RNAs in Lung Cancer: From Disease Markers to Treatment Roles.
复制标题
肺癌中的长非编码 RNA：从疾病标志物到治疗作用
DOI：
10.2147/cmar.s365762
复制
发表时间：
2022
影响因子：
3.3
通讯作者：
中科院分区：
文献类型：
--
作者：
由于肺癌目前的预后不良，迫切需要找到可用于早期诊断、预后预测的可靠生物标志物，并作为肺癌可能的治疗靶点。长非编码RNA（lncRNA）最近因其在癌发生、侵袭和转移中的潜在作用而引起了更多关注。讨论了肺癌中致癌和抑癌 lncRNA 的生物功能和调控机制。一些lncRNA已显示出良好的诊断价值，特别是与常规血清蛋白标记物结合时。反义寡核苷酸、小分子和 RNA 干扰技术的使用已显示出作为临床前研究中靶向 lncRNA 的直接治疗工具的前景。 lncRNA的生物标志物功能也可能间接参与肿瘤治疗，作为常规治疗的参考。总体而言，利用lncRNA作为肺癌预后和干预的生物标志物的概念仍处于起步阶段，只有更深入的研究才能产生显着的影响。
There is an urgent need to identify reliable biomarkers that can be used in early diagnosis, prognostication prediction and as possible therapeutic targets for lung cancer due to its current poor prognosis. Long noncoding RNAs (lncRNAs) have recently attracted additional attention due to their potential role in carcinogenesis, invasion and metastasis. Issues involved in the biofunctions and regulatory mechanisms of oncogenic and tumor-suppressive lncRNAs in lung cancer are discussed. Some lncRNAs have shown good diagnostic value, especially in combination with conventional serum protein markers. The use of antisense oligonucleotides, small molecules and RNA interference techniques have shown promise as direct therapeutic tools for targeting lncRNAs in preclinical studies. The biomarker function of lncRNAs may also indirectly involved in tumor therapy as a reference to conventional therapy. Overall, the concept of using lncRNAs as biomarkers for prognostication and intervention in lung cancer is still in its infancy, and only with more in-depth studies could they have a significant impact.